.Merck defeats incomes assumptions, raises sales outlook on solid demand for top medications like Keytruda CNBCMerck & Co. (MRK United States) Defeats Income Estimates as Keytruda Sales Increase BloombergMerck Stock: Pharma Giant Posts Sturdy End Results, Yet Overview Drops Short Investor's Organization DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck beats earnings as well as sales requirements amid Keytruda strong point, but provides mixed full-year expectation MarketWatch.